Express Pharma

JULY 8, 2024

In June 2024, the pharma and healthcare industry reported 76 deals worth $5B, compared to the last 12-month (June 2023 to May 2024) average of 95 deals worth $19B. million; NewGenIvf Group, to acquire COVIRIX Medical, a clinical-stage pharmaceutical company developing novel antiviral therapies for $617.3

Pharmaceutical Companies 88

Pharmaceutical Companies Pharmaceutical Companies Drug Development 88

Safe Biologics

DECEMBER 6, 2023

ASBM to Exhibit at ACR Convergence 2023 Visit ASBM at Booth #2612 at ACR Convergence in San Diego, CA, November 12-14th. Learn about ASBM’s recent educational activities surrounding IRA Medicare drug price negotiation, interchangeable biosimilars, and other key policy issues affecting patient access to medicines. Read it here.

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

pharmaphorum

JULY 6, 2023

In our penultimate video from ASCO 2023, Editor in Chief Jonah Comstock touches base with Biofourmis Chief Operating Officer Jaydev Thakkar. Biofourmis works with pharma on accelerating drug development and with post-market monitoring of approved drugs.

Drug Development 98

Drug Development 98

European Pharmaceutical Review

JANUARY 29, 2024

N-Nitrosamines By far the biggest issue bedevilling industry during 2023 was the continuing N-nitrosamine contamination saga, which was covered in the third issue of EPR 2023. In contrast, NDSRIs (N-Nitrosamine drug substance-related impurities) are still a burgeoning issue with many new NDSRIs being reported on a weekly basis.

Drug Development 111

Drug Development Vaccines Compounding 111

Safe Biologics

JULY 20, 2023

ASBM Chair Presents Poster Abstract at DIA Global Annual Meeting 2023 On June 26th, ASBM Chairman Ralph McKibbin presented a poster at the DIA Global Annual Meeting in Boston, MA. Morgan to discuss the IRA’s impact on drug development. REGISTER for the webinar here. View the agenda.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

ASBM Chair Presents Poster Abstract at DIA Global Annual Meeting 2023 On June 26th, ASBM Chairman Ralph McKibbin presented a poster at the DIA Global Annual Meeting in Boston, MA. Morgan to discuss the IRA’s impact on drug development. REGISTER for the webinar here. View the agenda.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

pharmaphorum

OCTOBER 11, 2023

Antifibrotic Drug Development Summit Mike.Hammerton Wed, 11/10/2023 - 09:11 Bookmark this

Drug Development 52

Drug Development 52

European Pharmaceutical Review

NOVEMBER 10, 2023

Exploring the complex pathway of paediatric drug development The formulation development of paediatric medications poses unique challenges compared to that of adult medications. The post Formulation In-Depth Focus 2023 appeared first on European Pharmaceutical Review.

Drug Development 97

Drug Development 97

European Pharmaceutical Review

MAY 11, 2023

The US Food and Drug Administration (FDA) has released a discussion paper to complement and inform future guidance on artificial intelligence (AI) and machine learning (ML) in drug development. On 2 May 2023, the FDA published draft guidance which included recommendations for delivering decentralised clinical trials.

Drug Development 104

Drug Development Pharmaceutical Manufacturing Communication 104

pharmaphorum

JUNE 22, 2023

Trials and tribulations of drug development: What does it take to establish new treatment for rare diseases? Mike.Hammerton Thu, 22/06/2023 - 08:00 Bookmark this

Drug Development 98

Drug Development 98

pharmaphorum

MAY 24, 2023

AI in drug development: A reality check Mike.Smith Wed, 05/24/2023 - 21:25 Bookmark this

Drug Development 92

Drug Development 92

pharmaphorum

NOVEMBER 14, 2023

6th Chronic Kidney Disease Drug Development Summit Mike.Hammerton Tue, 14/11/2023 - 17:44 Bookmark this

Drug Development 52

Drug Development 52

pharmaphorum

OCTOBER 11, 2023

7th Obesity & NASH Drug Development Summit Mike.Hammerton Wed, 11/10/2023 - 11:41 Bookmark this

Drug Development 52

Drug Development 52

European Pharmaceutical Review

DECEMBER 1, 2023

During CPHI Barcelona, EPR Editor Caroline Peachey asked Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, at Thermo Fisher Scientific about the dynamic landscape of pharmaceutical drug development. What are the trends affecting drug development today? What has been your highlight for 2023?

Drug Development 98

Drug Development Dosage Diabetes Process Improvement 98

European Pharmaceutical Review

FEBRUARY 22, 2023

Small companies will need to either defer development or find a partner willing to fund the confirmatory Phase III programme. 5 Psychedelic research: evaluating the fast-evolving regulatory roadmap Experience of accelerated drug development The other impediment to accelerated development is an increased focus on “long-term patient outcomes”.

Drug Development 97

Drug Development 97

pharmaphorum

SEPTEMBER 28, 2023

2nd Molecular Glue Drug Development Summit 2024 Mike.Hammerton Thu, 28/09/2023 - 10:08 Bookmark this

Drug Development 52

Drug Development 52

Express Pharma

NOVEMBER 1, 2023

Venus has won the FICCI Healthcare Award 2023 in the “Excellence in Patient Safety and Care” category. This model is poised to revolutionise drug development by reducing animal testing reliance, accelerating the drug approval pipeline, and tailoring patient-specific therapeutic strategies.”

Drug Development 82

Drug Development 82

pharmaphorum

OCTOBER 9, 2023

Champion Innovation at the 7th Dermatology Drug Development Summit Mike.Hammerton Mon, 09/10/2023 - 14:39 Bookmark this

Drug Development 52

Drug Development 52

pharmaphorum

JUNE 22, 2023

7th Complement-Based Drug Development Summit Mike.Hammerton Thu, 22/06/2023 - 12:58 Bookmark this

Drug Development 52

Drug Development 52

pharmaphorum

MAY 9, 2023

8th Microbiome Movement Drug Development Summit Mike.Hammerton Tue, 05/09/2023 - 09:16 Bookmark this

Drug Development 52

Drug Development 52

pharmaphorum

MAY 9, 2023

4th Dermatology Drug Development Summit Europe Mike.Hammerton Tue, 05/09/2023 - 20:11 Bookmark this

Drug Development 52

Drug Development 52

European Pharmaceutical Review

FEBRUARY 21, 2023

Included in this issue of European Pharmaceutical Review : FOREWORD Accelerating drug development David Elder, David P Elder Consultancy RAMAN SPECTROSCOPY Shining a light on Raman for microbiological analysis Tim Sandle, Bio Products Laboratory LIMS Overcoming barriers to capturing data in a laboratory Samantha Kanza, University of Southampton ENVIRONMENTAL (..)

Drug Development 111

Drug Development 111

pharmaphorum

MAY 26, 2023

5th RAS-Targeted Drug Development Summit Mike.Hammerton Fri, 05/26/2023 - 13:29 Bookmark this

Drug Development 52

Drug Development 52

pharmaphorum

MAY 10, 2023

4th Cytokine-Based Drug Development Summit Mike.Hammerton Wed, 05/10/2023 - 10:59 Bookmark this

Drug Development 52

Drug Development 52

pharmaphorum

JUNE 9, 2023

3rd Rare & Genetic Kidney Disease Drug Development Summit Mike.Hammerton Fri, 09/06/2023 - 07:13 Bookmark this

Drug Development 52

Drug Development 52

European Pharmaceutical Review

JULY 21, 2023

European Medicines Agency (EMA) has published a draft reflection paper on using artificial intelligence (AI) to support the safe and effective development, regulation and use of medicines.

Drug Development 98

Drug Development Documentation 98

PharmaTech

MARCH 21, 2023

A key hurdle for any drug development program is bringing the drug to clinical studies. Astute companies strategize past this milestone and plan for clinical and regulatory success.

Drug Development 40

Drug Development 40

Express Pharma

OCTOBER 12, 2023

In September 2023, the healthcare industry reported 53 deals worth $4.3 billion, compared to the last 12-month average (September 2022 to August 2023) of 82 deals worth $16.8 per cent of the total deal value during September 2023. per cent of the total deal value during September 2023.

Pharmaceutical Companies 89

Pharmaceutical Companies Pharmaceutical Companies Drug Development 89

European Pharmaceutical Review

APRIL 24, 2023

Included in this issue of European Pharmaceutical Review : FOREWORD New quality requirements for tobacco products David Elder, David P Elder Consultancy QA/QC MASS SPECTROMETRY The benefits of mass spectrometry for expediting biologics to patients Ian Anderson, Mostafa Zarei and Qifeng Zhang, Lonza IN-DEPTH FOCUS: Bioprocessing/Bioproduction Realising (..)

Drug Development 105

Drug Development 105

European Pharmaceutical Review

JANUARY 10, 2023

Clarivate Plc has released its Drugs to Watch 2023 report — among 70 of the drugs highlighted, including potential blockbuster drugs, the majority were revealed to be personalised medicines. The report offers predictive analysis of drugs entering the market or launching key indications in 2023.

Drug Development 98

Drug Development Diabetes 98

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. More information will be available soon. Mr. Spiegel is a founding member of ASBM and Executive Director of the Global Colon Cancer Association.

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

PharmExec

DECEMBER 8, 2022

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

Vaccines 119

Vaccines Drug Development 119

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028. Similarly, Almirall S.A.,

Vaccines 105

Vaccines Drug Development 105

European Pharmaceutical Review

NOVEMBER 9, 2023

MANUFACTURING Continuous direct compression: opening up faster access to oral dose medication Deborah McElhone, CPI’s Medicines Manufacturing Innovation Centre IN-DEPTH FOCUS: QA/QC MICROBIOLOGY Bioburden and sterility testing: how to conserve gene therapy product Kathy Zagaroli, Senior Director of Quality Control at Kiniksa Pharmaceuticals Tom Bujold, (..)

Biosimilars 98

Biosimilars Drug Development 98

Express Pharma

SEPTEMBER 20, 2023

In this video: Dhairy Sharma, Technical Sales, CILICANT Topic: Role of active packaging in drug development Key Takeaway: ACCUFLIP from Cilicant regulates Equilibrium Relative Humidity (ERH) within a specific range in order to protect medications from over-desiccation.

Packaging 52

Packaging Drug Development 52

STAT

OCTOBER 18, 2023

He shared some of that wisdom on Wednesday at the 2023 STAT Summit, from thoughts on how entrepreneurs can prepare themselves for the rough-and-tumble world of drug development to tips on raising money and dealing with the Food and Drug Administration. Continue to STAT+ to read the full story…

Drug Development 332

Drug Development 332

STAT

DECEMBER 22, 2023

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter  here.

HIPAA 264

HIPAA Drug Pricing Drug Development Hospitals 264